Distinguished in Teratoma of the Mediastinum

Patrizia Giannatempo

Milan, IT 
Distinguished in Teratoma of the Mediastinum
Milan, IT 
OverviewLocationsClinical Research

Overview

Patrizia Giannatempo practices in Milan, Italy. Ms. Giannatempo is rated as a Distinguished expert by MediFind in the treatment of Teratoma of the Mediastinum. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Penile Cancer, Cystectomy, and Orchiectomy.

Her clinical research consists of co-authoring 147 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Teratoma of the Mediastinum.

Gender
Female

Locations

Milan, Italy
Other Locations
Italiana, Italy
Messina, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
An Open Label, Single-arm, Phase 2 Study of Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel in Patients With Metastatic Urothelial Carcinoma After Chemotherapy Failure; the PEANUT Study
An Open Label, Single-arm, Phase 2 Study of Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel in Patients With Metastatic Urothelial Carcinoma After Chemotherapy Failure; the PEANUT Study
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).
Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).
Enrollment Status: Completed
Publish Date: May 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract
A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract
Enrollment Status: Completed
Publish Date: April 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

147 Total Publications

Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis.
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis.
Journal: Tumori
Published: August 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Giannatempo's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile